# Cellular Immunotherapy for Septic Shock: A Phase I Trial

> **NCT02421484** · PHASE1 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Septic Shock

## Interventions

- **BIOLOGICAL:** Allogeneic mesenchymal stromal cells

## Key facts

- **NCT ID:** NCT02421484
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-06
- **Final completion:** 2018-10-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02421484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02421484, "Cellular Immunotherapy for Septic Shock: A Phase I Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02421484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*